1. PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase
   Juan M. Alonso‐Dominguez et al, 2015, American Journal of Hematology CrossRef
2. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy
   TaeHyung Kim et al, 2017, Blood CrossRef
3. DNA Hypermethylation of Cell Cycle (p15 and p16) and Apoptotic (p14, p53, DAPK and TMS1) Genes in Peripheral Blood of Leukemia Patients
   Khaldon Bodoor et al, 2014, Asian Pacific Journal of Cancer Prevention CrossRef
4. Aberrant methylation and expression of DAPk1 in human hypopharyngeal squamous cell carcinoma
   Dong-Min Wei et al, 2015, Acta Oto-Laryngologica CrossRef
5. Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases
   Marcia Bellon et al, 2021, Molecular Cancer CrossRef
6. How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety
   Salvatore Perrone et al, 2016, Expert Opinion on Pharmacotherapy CrossRef
7. Death-associated protein kinase promoter methylation correlates with clinicopathological and prognostic features in nonsmall cell lung cancer patients
   Xiao-Yu Yang et al, 2018, Journal of Cancer Research and Therapeutics CrossRef
8. Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia
   Mathilde Ruggiu et al, 2018, Leukemia & Lymphoma CrossRef
9. Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemia
   Jing-Dong Zhou et al, 2015, Biochemical and Biophysical Research Communications CrossRef
10. Microsatellite Instability and Promoter Hypermethylation of DNA repair genes in Hematologic Malignancies: a forthcoming direction toward diagnostics
    Priyanjali Bhattacharya et al, 2018, Hematology CrossRef
11. Aberrant DNA Methylation in Chronic Myeloid Leukemia: Cell Fate Control, Prognosis, and Therapeutic Response
    Masumeh Maleki Behzad et al, 2018, Biochemical Genetics CrossRef
12. Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options
    Steffen Koschmieder et al, 2018, Seminars in Cancer Biology CrossRef
13. Perfil de metilación en pacientes con leucemia mieloide crónica: revisión sistemática
    Juliana Pérez Mejía et al, 2019, Hechos Microbiológicos CrossRef
14. The Implication of Cancer Progenitor Cells and the Role of Epigenetics in the Development of Novel Therapeutic Strategies for Chronic Myeloid Leukemia
    Stephanie M. Tortorella et al, 2015, Antioxidants & Redox Signaling CrossRef
15. Epigenetic silencing of the DAPK1 gene in Egyptian patients with chronic myeloid Leukemia
    Fatma M. Elsayed et al, 2020, Meta Gene CrossRef
16. Role of Epigenetics in Chronic Myeloid Leukemia
    Katerina Machova Polakova et al, 2013, Current Hematologic Malignancy Reports CrossRef
17. Quantitative detection of methylated NDRG4 gene as a candidate biomarker for diagnosis of colorectal cancer
    WENHUA XIAO et al, 2015, Oncology Letters CrossRef
18. Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML
    Jane Bugler et al, 2019, Frontiers in Cell and Developmental Biology CrossRef
19. Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia
    G Heller et al, 2016, Leukemia CrossRef
20. Significance of Somatic Mutation Profiling in CML Beyond BCR-ABL: A Retrospective Study of the Indian Population
    Pooja Chaudhary et al, 2024, Indian Journal of Hematology and Blood Transfusion CrossRef
21. Lack of Increased P15INK4BProtein Expression in Basal Cell Carcinomas
    Ahmed Ismail Hassan Moad et al, 2012, Asian Pacific Journal of Cancer Prevention CrossRef
22. Effect of bone marrow mesenchymal stem cells from blastic phase chronic myelogenous leukemia on the growth and apoptosis of leukemia cells
    YUXIANG HAN et al, 2013, Oncology Reports CrossRef
23. DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+CD15− cells in early chronic‐phase chronic myeloid leukemia
    Stéphanie Maupetit‐Mehouas et al, 2018, Molecular Oncology CrossRef
24. Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival
    Sameer Ahmad Guru et al, 2022, BMC Cancer CrossRef
25. Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis
    David Ghez et al, 2013, European Journal of Cancer CrossRef
26. Methylation analysis of the DAPK1 gene in imatinib-resistant chronic myeloid leukemia patients
    SELCEN CELIK et al, 2015, Oncology Letters CrossRef
27. Análisis de metilación en los genes supresores de tumores CDKN2B y DBC1 en pacientes colombianos con diagnóstico de leucemia
    Laura María Medina Gómez et al, 2016, Revista Colombiana de Cancerología CrossRef